Cancer Patents (Class 514/19.3)
  • Patent number: 11505579
    Abstract: The present invention relates to methods of treating a disease characterised by aberrant cell proliferation (e.g., a cancer) in a human subject in need thereof. In particular, the present invention relates to treating the above conditions by administering a therapeutically effective amount of at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon, and administering to the subject at least one agent that inhibits the Hedgehog (Hh) signalling pathway (e.g., Vismodegib). Also provided are pharmaceutical compositions, including controlled release pharmaceutical compositions, containing at least one agent that increases activation of a receptor of at least one type II interferon and/or type I interferon (e.g., a checkpoint inhibitor), an inhibitor of Hh signalling pathway, and a controlled release matrix such as a SiO2 matrix gel.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: November 22, 2022
    Assignee: ASCEND BIOPHARMACEUTICALS, INC.
    Inventors: Clement Leong, Geoffrey Pietersz
  • Patent number: 11498948
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: November 15, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11497740
    Abstract: Disclosed are methods for the use of Jumonji C demethylase inhibitors for the radiosensitization of cancers cells and the treatment and prevention of chemotherapy resistance in cancer.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 15, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maithili P Dalvi, Elisabeth D Martínez, John D Minna, Juan Bayo-Fina, Amit Das
  • Patent number: 11485765
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 1, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Helen Hoerzer, Oliver Schoor, Jens Fritsche, Harpreet Singh
  • Patent number: 11479807
    Abstract: The present technology relates generally to methods and compositions for targeted nucleic acid sequence enrichment, as well as uses of such enrichment for error-corrected nucleic acid sequencing applications. In some embodiments, highly accurate, error corrected and massively parallel sequencing of nucleic acid material is possible using a combination of uniquely labeled strands in a double-stranded nucleic acid complex in such a way that each strand can be informatically related to its complementary strand, but also distinguished from it following sequencing of each strand or an amplified product derived therefrom. In various embodiments, this information can be used for the purpose of error correction of the determined sequence.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 25, 2022
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: Scott R. Kennedy, Jesse J. Salk, Michael Hipp, Elizabeth Schmidt, Rosa Ana Risques, Daniela Nachmanson
  • Patent number: 11466072
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: October 11, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Lea Stevermann
  • Patent number: 11459394
    Abstract: The present invention is directed to binding molecules that possess one or more epitope-binding sites specific for an epitope of CD137 and one or more epitope-binding sites specific for an epitope of a tumor antigen (“TA”) (e.g., a “CD137×TA Binding Molecule”). In one embodiment, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific tetravalent diabodies, that are composed of two, three, four or more than four polypeptide chains and possessing two epitope-binding sites each specific for an epitope of CD137 and two epitope-binding sites each specific for an epitope of a TA. Alternatively, such CD137×TA Binding Molecules will be bispecific molecules, especially bispecific trivalent binding molecules composed of three or more polypeptide chains and possessing one or two epitope-binding sites each specific for an epitope of CD137 and one or two epitope-binding sites each specific for an epitope of a TA.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: October 4, 2022
    Assignee: MACROGENICS, INC.
    Inventors: Liqin Liu, Chia-Ying Kao Lam, Gundo Diedrich, Leslie S. Johnson, Paul A. Moore, Ezio Bonvini
  • Patent number: 11458127
    Abstract: Provided are methods of treating a brain tumor in a patient in need thereof comprising administering to the patient a compound described herein and radiation therapy and/or one or more additional therapeutic agents.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: October 4, 2022
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Joshua Murtie, Nelamangala Nagaraja, Brandon Nicolay, David Schenkein, Katharine Yen
  • Patent number: 11447539
    Abstract: FN3 domains that specifically bind to PD-L1, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Michael Diem, Rebecca Hawkins, Steven Jacobs, Manuel Sepulveda
  • Patent number: 11446321
    Abstract: The invention relates to a combination comprising an antineoplastic agent, e.g. an antimetabolite antineoplastic agent and a type 1 serotonin receptor (HTR1) modulator, e.g. a HTR1 antagonist. In addition the invention relates to a pharmaceutical composition comprising a combination of the invention and a pharmaceutically acceptable excipient. The invention also relates to the combination and pharmaceutical composition according to the invention for use in medicine, particularly for use in the prevention and/or treatment of a hematological malignancy.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: September 20, 2022
    Assignee: Leukos Biotech, S.L.
    Inventors: Ruth Muñoz Risueño, Mari Carmen Lara Castillo, Amaia Etxabe Alberdi
  • Patent number: 11440958
    Abstract: The present invention provides compositions comprising an anti-CD7 chimeric activating receptor (CAR) and an anti-CD7 protein expression blocker, and methods of using such compositions in cancer therapy.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: September 13, 2022
    Assignee: NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Yi Tian Png, Natasha Vinanica, Takahiro Kamiya, Dario Campana
  • Patent number: 11433098
    Abstract: The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: September 6, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michelle Monje-Deisseroth, Robbie Majzner, Crystal Mackall, Christopher Mount
  • Patent number: 11427932
    Abstract: This document relates to materials and methods for the production of protein. In one aspect, this document provides a nucleic acid construct including a first alcohol oxidase promoter element, wherein the first alcohol oxidase promoter element includes a mutation at one or more nucleotide positions corresponding to any of nucleotide positions 668-734 relative to SEQ ID NO: 28.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: August 30, 2022
    Assignee: Impossible Foods Inc.
    Inventors: Martin Andrew Hoyt, Xiao Guo, Smita Shankar
  • Patent number: 11414458
    Abstract: The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: August 16, 2022
    Assignees: Agenus Inc., The Board of Regents of the University of Oklahoma
    Inventors: Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hilderbrand, Oriana E. Hawkins
  • Patent number: 11400138
    Abstract: A method for improving a skin condition of a subject in need thereof includes administering to the subject a composition including a bioactive compound. The bioactive compound is a peptide, and includes at least one amino acid sequence as set forth in SEQ ID NO: 1 to SEQ ID NO: 11. Each of the amino acid sequence is a peptide of fish skin.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: August 2, 2022
    Assignee: TCI CO., LTD.
    Inventors: Yung-Hsiang Lin, Yu-Ling Wang
  • Patent number: 11382905
    Abstract: The present invention is directed to immune adjuvants containing IAP inhibitors, including Smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an IAP inhibitor and an antigen. Methods of enhancing an immune response by administration of an IAP inhibitor, methods of treating or preventing cancer, methods of treating or preventing infections, methods of treating autoimmune disorders, and methods of potentiating cytokine or antibody production are also provided.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: July 12, 2022
    Assignees: NOVARTIS AG, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Leigh Zawel, Christopher S. Straub, Brant G. Firestone, Glenn Dranoff, Michael Dougan
  • Patent number: 11340235
    Abstract: The invention relates to a method for binding or capturing autoantibodies directed to various Glycoprotein 2 (GP2) isoforms. In particular the invention provides an in vitro method for the diagnosis of an autoimmune disorder by the detection of autoantibodies that bind one or more isoforms of GP2. The invention is characterized by the provision of multiple isoforms of GP2 as autoantibody targets and encompasses the practical utilization of the finding that the isoform specificity of anti-GP2 autoantibodies enables determination of particular autoimmune diseases. The invention also provides a system and kit developed for carrying out the claimed method. The present invention is useful for determining whether a sample from an individual comprises autoantibodies associated with an autoimmune disease, and for differentiating between multiple autoimmune diseases that exhibit similar symptoms, such as Celiac disease (CeD), Crohn's disease (CD), primary sclerosing cholangitis (PSC), and/or ulcerative colitis (UC).
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: May 24, 2022
    Assignee: GA GENERIC ASSAYS GMBH
    Inventor: Dirk Roggenbuck
  • Patent number: 11339209
    Abstract: The invention provides novel compositions, methods, and therapeutic uses related to fusogenic protein MINION (microprotein inducer of fusion).
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: May 24, 2022
    Assignee: NOVARTIS AG
    Inventors: Stephane Corbel, Srihari Cidambi Sampath, Srinath Cidambi Sampath, Christian Schmedt, Qiao Zhang
  • Patent number: 11338027
    Abstract: The present invention provides a complex for use in the prevention and/or treatment of cancer, the complex comprising a) a cell penetrating peptide, b) at least one antigen or antigenic epitope, and c) at least one TLR peptide agonist, wherein the components a)-c) are covalently linked. In particular, compositions for use in the prevention and/or treatment of cancer, such as a pharmaceutical compositions and vaccines are provided.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: May 24, 2022
    Assignee: AMAL THERAPEUTICS SA
    Inventors: Madiha Derouazi, Elodie Belnoue
  • Patent number: 11326202
    Abstract: The present invention provides methods, compositions and kits for enriching and determining nucleotide sequences of a plurality of target loci from a sample comprising nucleic acids. The methods comprise one or more cycles of primer extension followed by PCR amplification of target sequences using nested target-specific primers.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: May 10, 2022
    Assignee: HELITEC LIMITED
    Inventor: Zongli Zheng
  • Patent number: 11285220
    Abstract: The present invention relates to protein drug conjugates, methods of manufacturing the same and their use in therapy. In particular, the present invention relates to protein drug conjugates comprising a globular protein, an improved linker and a drug for use in targeted drug delivery applications.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: March 29, 2022
    Assignee: Iksuda Therapeutics Limited
    Inventors: Anthony David Baxter, Christopher Michael Birchall, David James Mansell, Justyna Helena Mysliwy, Jenny Thirlway
  • Patent number: 11253568
    Abstract: Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin V to the subject.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: February 22, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Francis G. Blankenberg
  • Patent number: 11248252
    Abstract: Disclosed are composition and methods for treating immune disorders. Also disclosed are diagnosis methods and prognosis methods.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 15, 2022
    Inventors: Zhenglun Zhu, Hong Gao
  • Patent number: 11242375
    Abstract: Disclosed herein are cells that are immune cells or precursor cells thereof, which cells recombinantly express a chimeric antigen receptor (CAR), and a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, wherein the CAR binds to a cancer antigen. Also disclosed herein are T cells that recognize and are sensitized to a cancer antigen, which T cells recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response. Additionally provided are methods of using such cells to treat cancer in a subject in need thereof.
    Type: Grant
    Filed: September 2, 2016
    Date of Patent: February 8, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Prasad S. Adusumilli, Michel Sadelain
  • Patent number: 11229679
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: January 25, 2022
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer
  • Patent number: 11229711
    Abstract: Provided herein are antibody-cytotoxin antibody-drug conjugates and related compounds, such as linker-cytotoxin conjugates and the linkers used to make them, and intermediates in their synthesis; compositions; and methods, including methods of treating cancers.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 25, 2022
    Assignee: Magenta Therapeutics, Inc.
    Inventors: David Y. Jackson, Edward Ha
  • Patent number: 11230578
    Abstract: An isolated peptide is provided. The peptide comprises an amino acid sequence arranged in a space and configuration that allow interaction of the peptide with the DNA Binding Domain (DBD) of p53 through at least one residue of the DBD by which pCAP 250 (SEQ ID NO: 1) binds the DBD, wherein the peptide at least partially reactivates a mutant p53 protein, with the proviso that the peptide is not SEQ ID NO: 59-382.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 25, 2022
    Assignee: YEDA RESEARCH AND DEVELOPMENT CO. LTD.
    Inventors: Varda Rotter, Moshe Oren, Perry Tal, Shay Eizenberger, Avi Ben-Shimon
  • Patent number: 11203614
    Abstract: Disclosed herein are composite polypeptide. According to various embodiments, the composite polypeptide includes a parent polypeptide and a metal binding motif capable of forming a complex with a metal cation. The composite polypeptide may be conjugated with a linker unit having a plurality of functional elements to form a multi-functional molecular construct. Alternatively, multiple composite polypeptides may be conjugated to a linker unit to form a molecular construct, or a polypeptide bundle. Linker units suitable for conjugating with the composite polypeptide having the metal binding motif are also disclosed.
    Type: Grant
    Filed: March 25, 2020
    Date of Patent: December 21, 2021
    Assignee: IMMUNWORK INC.
    Inventors: Tse-Wen Chang, Hsing-Mao Chu, Wei-Ting Tian, Yueh-Hsiang Yu
  • Patent number: 11179450
    Abstract: A long-chain peptide antigen includes a plurality of epitopes. An interepitope sequence located between two of the plurality of epitopes contains four to ten consecutive tyrosines. The long-chain peptide antigen may be administered to a patient together with a hydrophobized polysaccharide, such as cholesterol-modified pullulan, and/or an adjuvant, such as CpG oligo DNA.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: November 23, 2021
    Assignees: MIE UNIVERSITY, KYOTO UNIVERSITY
    Inventors: Hiroshi Shiku, Naozumi Harada, Daisuke Muraoka, Kazunari Akiyoshi
  • Patent number: 11147819
    Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 19, 2021
    Assignee: Epizyme, Inc.
    Inventors: Scott Ribich, Michael Thomenius
  • Patent number: 11142561
    Abstract: Provided are methods, uses and pharmaceutical compositions for treatment of cancer with a B1SP fusion protein in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The cancer may be prostate cancer, breast cancer, ovarian cancer, bladder cancer, kidney cancer, glioblastoma or endometrial cancer. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the B1SP fusion protein may include a sema domain, a structural stabilization domain; and a half life extending moiety.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: October 12, 2021
    Assignee: The University of British Columbia
    Inventors: Christopher J. Ong, James William Peacock, Martin E. Gleave
  • Patent number: 11117931
    Abstract: An antimicrobial peptide has the amino acid sequence of SEQ ID NO: 1, except that i) the 1st and the 14th amino acids are deleted, ii) the 4th and the 8th amino acids are substituted with lysine (K), iii) the 7th amino acid is substituted with leucine (L), iv) the 9th amino acid is optionally substituted with lysine (K), and v) the 12th amino acid is optionally substituted with lysine (K). A method for antimicrobial treatment in a subject including administering a pharmaceutically effective amount of the antimicrobial peptide to a subject.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 14, 2021
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY
    Inventors: Yoonkyung Park, Min-Kyung Kim
  • Patent number: 11083774
    Abstract: The present invention provides a compound, preferably a peptide, having the following characteristics: a) consisting of 9 amino acids in a linear arrangement; b) of those 9 amino acids, 5 are cationic and 4 have a lipophilic R group; c) at least one of said 9 amino acids is a non-genetically coded amino acid (e.g. a modified derivative of a genetically coded amino acid); and optionally d) the lipophilic and cationic residues are arranged such that there are no more than two of either type of residue adjacent to one another; and further optionally e) the molecule comprises two pairs of adjacent cationic amino acids and one or two pairs of adjacent lipophilic residues; for use in the treatment of a tumour by combined, sequential or separate administration with an immune checkpoint inhibitor. The present invention further provides pharmaceutical packs or compositions comprising these active agents and methods of treating a tumour comprising administration of these active agents.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: August 10, 2021
    Assignee: LYTIX BIOPHARMA AS
    Inventors: Liv Marie Eike, Ketil Camilio, Baldur Sveinbjornsson, Laurence Zitvogel, Takahiro Yamazaki, Oystein Rekdal, John Sigurd Mjoen Svendsen
  • Patent number: 11045534
    Abstract: The present application relates to a novel immunity-inducing agent for treatment and/or prevention of cancer. Specifically, the present application provides an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity and selected from polypeptides derived from MCEMP1 and modified forms thereof, or a recombinant vector comprising a polynucleotide encoding the polypeptide and capable of expressing the polypeptide in vivo, and a method for inducing immunity, comprising administering the immunity-inducing agent to a subject.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: June 29, 2021
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayuki Fujita, Fumiyoshi Okano
  • Patent number: 11028136
    Abstract: The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient. The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 8, 2021
    Assignees: Sapporo Medical University, Medical & Biological Laboratories Co., Ltd.
    Inventors: Toshihiko Torigoe, Eri Atsuyama, Hironori Otaka, Kazue Nakano, Dongliang Li, Shingo Toji, Takuya Asano, Ryota Horibe, Yoshihiko Hirohashi, Noriyuki Sato, Tsuyoshi Saito
  • Patent number: 10987295
    Abstract: Provided is a novel peptide and a cosmetic composition for inhibiting a skin-aging or a skin-wrinkle formation including the same. The peptide has activities for facilitating the bindings between keratinocytes; and increasing the expressions of junction proteins significantly.
    Type: Grant
    Filed: June 23, 2020
    Date of Patent: April 27, 2021
    Assignee: College of Medicine Pochon CHA University Industry-Academic Cooperation Foundation
    Inventors: Ji-Hyung Chung, Da-Yoon Chung
  • Patent number: 10982259
    Abstract: Differential expression of long non-coding RNAs (lncRNAs) and enhancer RNAs (eRNAs) are used to monitor diseases and determine therapeutic efficacy in, for example, neurological diseases, inflammatory diseases, rheumatic diseases, and autoimmune diseases. Machine learning systems are used to identify lncRNAs or eRNAs having differential expression correlated with responsiveness to various therapies.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: April 20, 2021
    Assignee: IQUITY, INC.
    Inventor: Charles Floyd Spurlock, III
  • Patent number: 10981954
    Abstract: The present application provides an inhibitory compound, such as a peptide, and methods for using the inhibitory compound in the treatment, diagnosis or monitoring of cognitive and mood disorders that are typically associated with memory loss and/or loss of executive function. In one example, the inhibitory compound is a peptide that mimics the N-terminal sequence of the intracellular loop of ?5 subunit of ?5GABAA receptors. Also provided are compositions and methods for treating a disorder associated with memory loss or loss of executive function. The therapeutic method comprises the step of inhibiting binding of radixin to ?5GABAA receptors, for example, by administration of the presently described inhibitory compound or peptide.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 20, 2021
    Assignees: The Governing Council of the University of Toronto, Banting Institute
    Inventors: Gang Lei, Beverley Anne Orser
  • Patent number: 10960082
    Abstract: Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n??I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II, wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: March 30, 2021
    Assignee: NEWBIO THERAPEUTICS, INC.
    Inventors: Deqiang An, Nianhe Han, Di Zeng, Hang Yang, Peng Zhu, Mingzhen Li, Li Jian, Chun Yang
  • Patent number: 10905728
    Abstract: Extracts of Agaricus blazei Murill have been found to have anti-tumor activity. In particular, a polar, high molecular weight fraction of an Agaricus blazei Murill extract has been found which has an inhibitory effect on legumain activity. Extracts of Agaricus blazei Murill can be used in a pharmaceutical composition to inhibit cysteine protease legumain in a patient suffering from a tumor thereby treating the tumor and preventing new tumors.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 2, 2021
    Assignee: Immunopharma AS
    Inventors: Anne Berit Calmeyer Samuelsen, Lise Berven
  • Patent number: 10874678
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 29, 2020
    Assignees: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10845359
    Abstract: The present invention relates to a method for analyzing the activation state of a signaling pathway in a cell or tissue separated from a subject through real time single molecule protein-protein interaction analysis, and a method for selecting a personalized medicine or predicting a therapeutic efficacy to a medicine using the same.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: November 24, 2020
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tae-Young Yoon, Hong Won Lee
  • Patent number: 10836795
    Abstract: A peptide derived from the copine 7 protein and having both cell permeability and bone tissue regeneration ability, and a use of the peptide, are described. The peptide has excellent bone tissue regeneration ability and is therefore useful for treating a disease requiring bone regeneration, such as osteoporosis. Particularly, by also having cell permeability, the peptide does not require the attachment of a separate peptide or addition of another preparation for the cell permeation thereof and thus can be conveniently applied in orthopedics and the like requiring various surgical regeneration treatments.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: November 17, 2020
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee, Joocheol Park
  • Patent number: 10829735
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: November 10, 2020
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Patent number: 10782294
    Abstract: Isolated peptides and compositions comprising same are provided. Further, methods for targeting mitochondria in a cell, methods for assessing mitochondrial function in a cell and methods for diagnosing mitochondria associated diseases are provided.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 22, 2020
    Assignee: TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED
    Inventors: Arnon Henn, Boris Shneyer, Andreas Reichert
  • Patent number: 10768179
    Abstract: It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can be administered to a cancer patient selected with functional suppression of CBP as an index.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: September 8, 2020
    Assignees: National Cancer Center, Daiichi Sankyo Company, Limited
    Inventors: Takashi Kohno, Hideaki Ogiwara, Yuichi Tominaga, Saito Higuchi
  • Patent number: 10766942
    Abstract: The present invention provides an anti-angiogenic peptide comprising an amino acid sequence having at least 70% identity to amino acid residues 123-140 of SEQ ID NO 1 or amino acid residues 24-141 of SEQ ID NO 2. The invention also provides nucleic acid constructs encoding such peptides, and vectors and cells comprising such nucleic acid constructs. The invention further provides pharmaceutical compositions comprising the peptides or nucleic acid constructs of the invention, and the use of peptides, nucleic acid constructs or pharmaceutical compositions of the invention to treat diseases associated with angiogenesis.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: September 8, 2020
    Assignee: Queen Mary University of London
    Inventors: James Whiteford, Giulia De Rossi
  • Patent number: 10752893
    Abstract: The invention relates to methods for isolating traffic-enhancing mutants of drug delivery proteins. In one embodiment, the invention provides a carrier for delivering a therapeutic agent to an organelle, comprising a polypeptide encoded by a mutant penton base gene. In another embodiment, the invention provides a method of enhancing trafficking to a cell by administering a composition comprising a penton base (PB) protein with one or more mutations that enhance cellular entry.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: August 25, 2020
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventor: Lali K. Medina-Kauwe
  • Patent number: 10744180
    Abstract: Compositions, kits and methods for preventing or treating cystic fibrosis are provided, which include the use of a peptidomimetic that inhibits the interaction between CAL and mutant CFTR proteins.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: August 18, 2020
    Assignee: TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Dean R. Madden, Nicholas P. Gill, Carrie Ann Davison, Mark R. Spaller
  • Patent number: 10722593
    Abstract: Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharmaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed herein can be used to treat diseases such as bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, lung cancer, melanoma, non-Hodgkin lymphoma, glioblastoma, pancreatic cancer, prostate cancer, and thyroid cancer.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: July 28, 2020
    Assignee: SIRENAS LLC
    Inventors: Oliver Booth Vining, Venkata Rami Reddy Macherla, Alexander Wayne Schammel, Ippei Usui, Jacob Neal Beverage, Elizabeth Paige Stout, Bryan Junn Lee, Steven Bruce Cohen, Eduardo Esquenazi